-
Published 11/20/2025
Tosi HM, Zheng C, Tarren AH, Yellanki M, Miller SJ, Soloviev OV, Corrigan JK, Schneeloch GR, Katki HA, Kearney LE, Caverly TJ, Tanner NT, Wiener RS, Brophy M, Fillmore NR, Do NV, Elbers DC. Rapid Support and Implementation of an Application for the Prediction Augmented Screening Initiative (PASI) Planning Phase Through the Enabling Technologies for Rapid Learning Health Systems Platform (ENTHRALL) at the Department of Veterans Affairs (VA). Cancer Inform. 2025; 24:11769351251389781. PMID: 41281611.
-
Published 11/20/2025
Ferri GM, Yildirim C, Do NV, Brophy MT, Munshi NC, Edwards CV, Fillmore NR. Moderate-Severe Thrombocytopenia Portends Poor Outcomes in Multiple Myeloma. EJHaem. 2025 Dec; 6(6):e70153. PMID: 41278511.
-
Published 11/17/2025
Barry A, England BR, Sayles H, Helget LN, Androsenko M, Wu H, Michaud K, Kramer B, Newcomb JA, Brophy MT, Davis-Karim A, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, O'Dell JR, Mikuls TR. Improvements in Health-Related Quality of Life With Treat-to-Target Urate-Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial. Arthritis Care Res (Hoboken). 2026 Feb; 78(2):259-269. PMID: 40771143.
-
Published 9/1/2025
La J, Hshieh T, Hamparsumian A, Zwolinski R, Wood J, Dharne M, Gaziano JM, Brophy MT, Do NV, Munshi NC, Driver JA, Abel GA, Fillmore NR, DuMontier C. Potentially Inappropriate Medications, Frailty, and Outcomes in Patients With Cancer Managed in a National Health Care System. J Natl Compr Canc Netw. 2025 Sep; 23(9):363-370. PMID: 40930142.
-
Published 8/5/2025
Kohn S, Sayles H, Helget LN, England BR, Roul P, Newcomb JA, Kramer B, Davis-Karim A, Brophy MT, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, Wu H, O'Dell JR, Mikuls TR. Real-world persistence of urate-lowering therapy following a treat-to-target intervention: A two-year follow-up analysis of the STOP gout trial. Semin Arthritis Rheum. 2025 Oct; 74:152800. PMID: 40782426.